| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―May―26 |
Do angiotensin-converting enzyme inhibitors reduce the risk of death in COVID-19? Yes |
Mykola Khalangot |
| 2 |
[GO] |
2026―Mar―30 |
Trends of new diagnosis and treatment initiation of hypertension during the COVID-19 pandemic in Korea |
Jaeyong Lee, Ari Lee, Moses Song, Jiyen Han, Kyoung Hwa Ha, Hyeok-Hee Lee, Seng Chan You, Hyeon Chang Kim, Hokyou Lee |
| 3 |
[GO] |
2026―Feb―27 |
Response to correspondence on “Prevalence of hypertension and related factors among suspected hypertensive medical personnel during COVID-19 vaccination” |
Sittichai Khamsai, Nat Leelawiwat, Praew Kotruchin, Wantin Sribenjalux, Phitphiboon Deawtrakulchai, Somchai Ruangwannasak, Kittisak Sawanyawisuth |
| 4 |
[GO] |
2026―Feb―06 |
Comment on “Prevalence of hypertension and related factors among suspected hypertensive medical personnel during COVID-19 vaccination” |
Fengyu Chen, Chunming Zhang, Kan Kan, Zejun Xue, Jun Zhang |
| 5 |
[GO] |
2026―Jan―14 |
“Implementation Hypertension” in the pandemic era: unmasking white-coat effects in healthcare workers |
Emi Ushigome, Michiaki Fukui |
| 6 |
[GO] |
2025―Dec―02 |
Response to the Letter Regarding Our Editorial: “Impact of SARS-CoV-2 variants on viral infectivity and the role of the Renin-Angiotensin-Aldosterone system” |
Yasushi Matsuzawa, Kenichi Tsujita |
| 7 |
[GO] |
2025―Dec―02 |
Renin-angiotensin-aldosterone system inhibitors - why they won’t help in COVID-19 |
Chia Siang Kow, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam |
| 8 |
[GO] |
2025―Oct―14 |
Prevalence of hypertension and related factors among suspected hypertensive medical personnel during COVID-19 vaccination |
Sittichai Khamsai, Nat Leelawiwat, Praew Kotruchin, Wantin Sribenjalux, Phitphiboon Deawtrakulchai, Somchai Ruangwannasak, Kittisak Sawanyawisuth |
| 9 |
[GO] |
2025―Oct―08 |
Comment on “Indirect effect of the COVID-19 pandemic on cardiovascular diseases incidence, mortality, and healthcare use among patients with hypertension but without SARS-CoV-2 infection in Hong Kong” |
Hinpetch Daungsupawong, Viroj Wiwanitkit |
| 10 |
[GO] |
2025―Oct―03 |
Correction: Effect of the renin-angiotensin-aldosterone system inhibitors on time to nucleic acid negative conversion in hypertensive patients with SARS-CoV-2 omicron infection: a propensity score matching study |
Ru Wen, Jingwen Li, Fengxi Chen, Jian Liu, Peng Xu, Mengfei Li, Jingwei Li, Liang Tan, Chen Liu |
| 11 |
[GO] |
2025―May―23 |
Indirect effect of the COVID-19 pandemic on cardiovascular diseases incidence, mortality, and healthcare use among patients with hypertension but without SARS-CoV-2 infection in Hong Kong: an interrupted time series analysis |
Zhuoran Hu, Yuk Kam Yau, Jianchao Quan, Karen Ann Grépin, Ivy Lynn Mak, Gary Kui Kai Lau, Ian Chi Kei Wong, David Vai Kiong Chao, Welchie Wai Kit Ko, Chak Sing Lau, Cindy Lo Kuen Lam, Eric Yuk Fai Wan |
| 12 |
[GO] |
2025―Jan―28 |
Impact of SARS-CoV-2 variants on viral infectivity and the role of the renin-angiotensin-aldosterone system |
Yasushi Matsuzawa, Kenichi Tsujita |
| 13 |
[GO] |
2025―Jan―08 |
Association between equivalized annual household income and regular medical visits for hypertensive patients since the COVID-19 outbreak |
Maya Toyama, Michihiro Satoh, Hideaki Hashimoto, Yutaro Iwabe, Takahito Yagihashi, Shingo Nakayama, Takahisa Murakami, Naoki Nakaya, Hirohito Metoki, Atsushi Hozawa, Takahiro Tabuchi |
| 14 |
[GO] |
2024―Dec―23 |
Rethinking angiotensin receptor blocker (ARB) use in COVID-19: a class-wide call for careful dosing |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam |
| 15 |
[GO] |
2024―Dec―23 |
Response to the correspondence: Rethinking angiotensin receptor blocker (ARB) use in COVID-19: a class-wide call for careful dosing |
Fumiki Yoshihara |
| 16 |
[GO] |
2024―Nov―06 |
Effect of the renin-angiotensin-aldosterone system inhibitors on time to nucleic acid negative conversion in hypertensive patients with SARS-CoV-2 omicron infection: a propensity score matching study |
Ru Wen, Jinwen Li, Fengxi Chen, Jian Liu, Peng Xu, Mengfei Li, Jingwei Li, Liang Tan, Chen Liu |
| 17 |
[GO] |
2024―Aug―01 |
Shadow left by COVID-19 pandemic on the future |
Hisashi Kai |
| 18 |
[GO] |
2024―Jul―01 |
The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks |
Takahiro Okumura, Toyoaki Murohara |
| 19 |
[GO] |
2024―Jun―03 |
The trends of antihypertensive drug prescription based on the Japanese national data throughout the COVID-19 pandemic period |
Shotaro Natsume, Michihiro Satoh, Takahisa Murakami, Masato Sasaki, Hirohito Metoki |
| 20 |
[GO] |
2024―Apr―26 |
Relationship between 2nd-generation angiotensin receptor blockers and the risk of hypotension in COVID-19 patients admitted to hospital |
Fumiki Yoshihara, Yasushi Matsuzawa, Kiyomasa Nakatsuka, Jin Kirigaya, Ichiro Takeuchi, Kazuo Kimura, Masaaki Konishi, Kouichi Tamura, Kazuki Fukui, Kengo Tsukahara, Hiroyuki Shimizu, Keisuke Iwabuchi, Yu Yamada, Kenichiro Saka, Yukihito Sato, Masahiro Ogawa, Kayoko Hayakawa, Norio Ohmagari, Syuhei Ikeda, Masaharu Akao, Hideki Shimomura, Yasuki Kihara, Akihiro Yoshimoto, Masanori Morita, Norihiko Kumada, Soshiro Ogata, Kunihiro Nishimura, Tetsuya Arisato, Miki Matsuo, Masatsugu Kishida, Satoshi Yasuda, Hisao Ogawa |
| 21 |
[GO] |
2024―Jan―31 |
The necessity of investigations to clarify sex and racial disparities in pathophysiology of Long COVID |
Chisa Matsumoto |
| 22 |
[GO] |
2023―Dec―25 |
Association between blood pressure and COVID-19 severity |
Fumiki Yoshihara |
| 23 |
[GO] |
2023―Dec―04 |
Uninterrupted medical care against disasters and pandemics |
Tomomi Hasebe, Naoyuki Hasebe |
| 24 |
[GO] |
2023―Nov―29 |
Mitigating secondary disaster triggered by fear of COVID-19: the role of professional medical societies |
Yasushi Matsuzawa, Kenichi Tsujita |
| 25 |
[GO] |
2023―Nov―17 |
Calcium channel blockers may reduce the development of long COVID in females |
Takuya Ozawa, Ryusei Kimura, Hideki Terai, Ryo Takemura, Ho Namkoong, Masahiro Kondo, Keitaro Fukuda, Kazuma Yagi, Takanori Asakura, Katsunori Masaki, Shotaro Chubachi, Jun Miyata, Keiko Ohgino, Ichiro Kawada, Junko Kagyo, Toshio Odani, Naota Kuwahara, Ichiro Nakachi, Makoto Ishii, Yasunori Sato, Koichi Fukunaga |
| 26 |
[GO] |
2023―Nov―02 |
Prognostic significance of hypertension history and blood pressure on admission in Japanese patients with coronavirus disease 2019: integrative analysis from the Japan COVID-19 Task Force |
Kaori Sakurai, Shotaro Chubachi, Takanori Asakura, Ho Namkoong, Hiromu Tanaka, Shuhei Azekawa, Takashi Shimada, Shiro Otake, Kensuke Nakagawara, Takahiro Fukushima, Ho Lee, Mayuko Watase, Tatsuya Kusumoto, Katsunori Masaki, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Yukinori Okada, Ryuji Koike, Yuko Kitagawa, Akinori Kimura, Seiya Imoto, Satoru Miyano, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga |
| 27 |
[GO] |
2023―Oct―23 |
The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients |
Qiaoqiao Zhou, Lei Zhang, Yanming Dong, Yuan Wang, Bin Zhang, Shiyi Zhou, Qing Huang, Tian Wu, Gongxuan Chen |
| 28 |
[GO] |
2023―Jul―18 |
Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study |
Ryosuke Miura, Kouji Okada |
| 29 |
[GO] |
2023―Jul―13 |
Reply to: Microvascular hypertensive disease, long COVID, and end-organ pathology |
Chisa Matsumoto |
| 30 |
[GO] |
2023―Jul―13 |
Microvascular hypertensive disease, Long COVID, and end-organ pathology |
Nevio Cimolai |
| 31 |
[GO] |
2023―Jun―12 |
Correction to: Preeclampsia and COVID-19 in Afghanistan: additional burden on Afghan pregnant women’s health |
Nooria Mohammady, Sayed Hamid Mousavi, Fatema Rezaie, Huma Homam |
| 32 |
[GO] |
2023―May―26 |
Preeclampsia and COVID-19 in Afghanistan: additional burden on Afghan pregnant women’s health |
Nooria Mohammady, Sayed Hamid Mousavi, Fatima Rezaie, Huma Homam |
| 33 |
[GO] |
2023―Mar―30 |
Hypertension management before and under the COVID-19 pandemic: lessons and future directions |
Yoichi Nozato, Koichi Yamamoto, Hiromi Rakugi |
| 34 |
[GO] |
2023―Feb―27 |
Reply to: Hypertension and severe COVID-19 |
Shigeru Shibata, Kei Asayama |
| 35 |
[GO] |
2023―Feb―27 |
Hypertension and severe COVID-19 |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 36 |
[GO] |
2022―Dec―27 |
Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19 |
Chisa Matsumoto, Shigeru Shibata, Takuya Kishi, Satoshi Morimoto, Masaki Mogi, Koichi Yamamoto, Kazuo Kobayashi, Masami Tanaka, Kei Asayama, Eiichiro Yamamoto, Hironori Nakagami, Satoshi Hoshide, Masashi Mukoyama, Kazuomi Kario, Koichi Node, Hiromi Rakugi |
| 37 |
[GO] |
2022―Dec―23 |
COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19 |
Shigeru Shibata, Kazuo Kobayashi, Masami Tanaka, Kei Asayama, Eiichiro Yamamoto, Hironori Nakagami, Satoshi Hoshide, Takuya Kishi, Chisa Matsumoto, Masaki Mogi, Satoshi Morimoto, Koichi Yamamoto, Masashi Mukoyama, Kazuomi Kario, Koichi Node, Hiromi Rakugi |
| 38 |
[GO] |
2022―Nov―15 |
Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension |
Kengo Azushima, Hiromichi Wakui, Kouichi Tamura |
| 39 |
[GO] |
2022―Oct―24 |
Therapeutic target and clinical impact of day-to-day blood pressure variability in hypertensive patients with covid-19 |
Gusti Ngurah Prana Jagannatha, A. A. A. Dwi Adelia Yasmin, I. Wayan Agus Surya Pradnyana, Stanly Kamardi, I. Gusti Bagus Mulia Agung Pradnyaandara, Elinardo Enrique Pangkahila, Gede Odi Bayu Dharma Perkasa, Ida Bagus Satriya Wibawa |
| 40 |
[GO] |
2022―Oct―14 |
The relationship between changes in exercise habits and psychosomatic activities in older hypertensive patients during the COVID-19 pandemic |
Yukiko Yasunobe, Hiroshi Akasaka, Koichi Yamamoto, Yuri Onishi, Tomohiro Minami, Shino Yoshida, Hiromi Rakugi |
| 41 |
[GO] |
2022―Sep―05 |
Effect of COVID-19 pandemic on seasonal cardiovascular mortality in Japan, and Asian evidence |
Kazuomi Kario, Masaki Mogi, Satoshi Hoshide |
| 42 |
[GO] |
2022―Jul―15 |
Severe COVID-19 and preexisting hypertension: a matter of age? |
Osamu Yamazaki, Shigeru Shibata |
| 43 |
[GO] |
2022―Jun―20 |
Time-series analysis of blood pressure changes after the guideline update in 2019 and the coronavirus disease pandemic in 2020 using Japanese longitudinal data |
Michihiro Satoh, Takahisa Murakami, Taku Obara, Hirohito Metoki |
| 44 |
[GO] |
2022―May―18 |
Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19 |
Yasushi Matsuzawa, Kazuo Kimura, Hisao Ogawa, Kouichi Tamura |
| 45 |
[GO] |
2022―Mar―29 |
The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19 |
Ewan McFarlane, Marijke Linschoten, Folkert W. Asselbergs, Peter S. Lacy, Dawid Jedrzejewski, Bryan Williams |
| 46 |
[GO] |
2022―Mar―10 |
The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness |
Dimitrios Terentes-Printzios, Vasiliki Gardikioti, Eirini Solomou, Eleni Emmanouil, Ioanna Gourgouli, Panagiotis Xydis, Georgia Christopoulou, Christos Georgakopoulos, Ioanna Dima, Antigoni Miliou, George Lazaros, Maria Pirounaki, Konstantinos Tsioufis, Charalambos Vlachopoulos |
| 47 |
[GO] |
2022―Feb―28 |
Is COVID-19 vaccination beneficial or harmful to endothelial cells? |
Masaki Mogi |
| 48 |
[GO] |
2022―Feb―18 |
Anxiety and hypertension in the COVID-19 era: how is the central autonomic network linked? |
Michiaki Nagai, Masaya Kato, Dote Keigo |
| 49 |
[GO] |
2022―Jan―21 |
Anxiety, home blood pressure monitoring, and cardiovascular events among older hypertension patients during the COVID-19 pandemic |
Shuyuan Zhang, Yixuan Zhong, Lixin Wang, Xinhua Yin, Yufeng Li, Yunlan Liu, Qiuyan Dai, Anli Tong, Dongfeng Li, Liangqing Zhang, Ping Li, Guohui Zhang, Rongjie Huang, Jinguang Liu, Luosha Zhao, Jing Yu, Xinjun Zhang, Li Yang, Jun Cai, Weili Zhang |
| 50 |
[GO] |
2021―Dec―24 |
Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan |
Kazuo Kobayashi, Keiichi Chin, Shinichi Umezawa, Shun Ito, Hareaki Yamamoto, Shiro Nakano, Nobukazu Takada, Nobuo Hatori, Kouichi Tamura |
| 51 |
[GO] |
2021―Dec―17 |
How to deal with hypertension in the COVID-19 era-the impact “ON” and “OF” hypertension |
Mari Ishida |
| 52 |
[GO] |
2021―Dec―02 |
Impact of the COVID-19 pandemic on blood pressure control: a nationwide home blood pressure monitoring study |
Fabiana G. A. M. Feitosa, Audes D. M. Feitosa, Annelise M. G. Paiva, Marco A. Mota-Gomes, Weimar S. Barroso, Roberto D. Miranda, Eduardo C. D. Barbosa, Andréa A. Brandão, José L. Lima-Filho, Andrei C. Sposito, Antonio Coca, Wilson Nadruz |
| 53 |
[GO] |
2021―Nov―30 |
Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients |
Prakash G. Kulkarni, Amul Sakharkar, Tanushree Banerjee |
| 54 |
[GO] |
2021―Nov―18 |
Coronary calcium score as a predictor of outcomes in the hypertensive Covid-19 population: results from the Italian (S) Core-Covid-19 Registry |
Alberto Cereda, Marco Toselli, Anna Palmisano, Davide Vignale, Arif Khokhar, Gianluca Campo, Matteo Bertini, Marco Loffi, Daniele Andreini, Gianluca Pontone, Gianluigi Patelli, Giuseppe Massimo Sangiorgi, Gabriele Tumminello, Mariarosa Elia, Attilio Iacovoni, Stefano Carugo, Claudio Rapezzi, Antonio Colombo, Francesco Giannini, Antonio Esposito |
| 55 |
[GO] |
2021―Nov―09 |
Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 56 |
[GO] |
2021―Jun―08 |
Therapeutic vaccine for chronic diseases after the COVID-19 Era |
Hironori Nakagami, Hiroki Hayashi, Munehisa Shimamura, Hiromi Rakugi, Ryuichi Morishita |
| 57 |
[GO] |
2021―May―20 |
Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials |
Chia Siang Kow, Long Chiau Ming, Syed Shahzad Hasan |
| 58 |
[GO] |
2021―Feb―03 |
Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19 |
Hao Wang, Xuming Sun, Jessica L. VonCannon, Neal D. Kon, Carlos M. Ferrario, Leanne Groban |
| 59 |
[GO] |
2021―Jan―20 |
Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review |
Nitalia Naidoo, Jagidesa Moodley, Thajasvarie Naicker |
| 60 |
[GO] |
2021―Jan―06 |
The association between blood pressure levels and mortality in critically ill patients with COVID-19 in Wuhan, China: a case-series report |
Li Geng, Chao He, Hao Kan, Ka Zhang, Aiqin Mao, Chi Zhang, Zhiwei Wang, Bo Wei, Tingting Zhou, Xin Wen, Fan Yu, Wenfang Li, Lei Feng |
| 61 |
[GO] |
2021―Jan―05 |
Further promotion of “the JSH plan for the future” conscious of new normal after/with COVID-19: message from the new president of the Japanese Society of Hypertension |
Hiromi Rakugi |
| 62 |
[GO] |
2020―Nov―02 |
The pivotal role of the angiotensin-II-NF-κB axis in the development of COVID-19 pathophysiology |
Hiroshi Okamoto, Naomi Ichikawa |
| 63 |
[GO] |
2020―Aug―27 |
Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China |
Jinjun Ran, Ying Song, Zian Zhuang, Lefei Han, Shi Zhao, Peihua Cao, Yan Geng, Lin Xu, Jing Qin, Daihai He, Fengfu Wu, Lin Yang |
| 64 |
[GO] |
2020―Aug―21 |
Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study |
Yasushi Matsuzawa, Hisao Ogawa, Kazuo Kimura, Masaaki Konishi, Jin Kirigaya, Kazuki Fukui, Kengo Tsukahara, Hiroyuki Shimizu, Keisuke Iwabuchi, Yu Yamada, Kenichiro Saka, Ichiro Takeuchi, Toshio Hirano, Kouichi Tamura |
| 65 |
[GO] |
2020―Jul―31 |
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
Shigeru Shibata, Hisatomi Arima, Kei Asayama, Satoshi Hoshide, Atsuhiro Ichihara, Toshihiko Ishimitsu, Kazuomi Kario, Takuya Kishi, Masaki Mogi, Akira Nishiyama, Mitsuru Ohishi, Takayoshi Ohkubo, Kouichi Tamura, Masami Tanaka, Eiichiro Yamamoto, Koichi Yamamoto, Hiroshi Itoh |
| 66 |
[GO] |
2020―Jun―18 |
A new normal for hypertension medicine with coronavirus disease-2019 (COVID-19): proposal from the president of the Japanese Society of Hypertension |
Hiroshi Itoh |
| 67 |
[GO] |
2020―Jun―10 |
SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs |
Michele M. Ciulla |
| 68 |
[GO] |
2020―Jun―01 |
COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study |
Songjiang Huang, Jianwen Wang, Fen Liu, Jiacheng Liu, Guijuan Cao, Chongtu Yang, Wei Liu, Chao Tu, Muxin Zhu, Bin Xiong |
| 69 |
[GO] |
2020―May―22 |
Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? |
François Silhol, Gabrielle Sarlon, Jean-Claude Deharo, Bernard Vaïsse |
| 70 |
[GO] |
2020―May―20 |
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19 |
Masato Furuhashi, Norihito Moniwa, Hideki Takizawa, Nobuyuki Ura, Kazuaki Shimamoto |
| 71 |
[GO] |
2020―Apr―30 |
A novel COVID-19 and its effects on cardiovascular disease |
Arumugam Paramasivam, Jayaseelan Vijayashree Priyadharsini, Subramanian Raghunandhakumar, Perumal Elumalai |
| 72 |
[GO] |
2020―Apr―27 |
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 |
Hisashi Kai, Mamiko Kai |
| 73 |
[GO] |
2020―Mar―30 |
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension |
Gang Li, Rui Hu, Xuejiao Zhang |
|
